Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction by Jander, Nikolaus et al.
Valvular Heart Disease
Outcome of Patients With Low-Gradient “Severe” Aortic
Stenosis and Preserved Ejection Fraction
Nikolaus Jander, MD*; Jan Minners, MD, PhD*; Ingar Holme, PhD; Eva Gerdts, MD, PhD;
Kurt Boman, MD, PhD; Philippe Brudi, MD; John B. Chambers, MD; Kenneth Egstrup, MD, PhD;
Y. Antero Kesa¨niemi, MD, PhD; William Malbecq, PhD; Christoph A. Nienaber, MD; Simon Ray, MD;
Anne Rossebø, MD; Terje R. Pedersen, MD, PhD; Terje Skjærpe, MD, PhD;
Ronnie Willenheimer, MD, PhD; Kristian Wachtell, MD, PhD;
Franz-Josef Neumann, MD; Christa Gohlke-Ba¨rwolf, MD
Background—Retrospective studies have suggested that patients with a low transvalvular gradient in the presence of an
aortic valve area1.0 cm2 and normal ejection fraction may represent a subgroup with an advanced stage of aortic valve
disease, reduced stroke volume, and poor prognosis requiring early surgery. We therefore evaluated the outcome of
patients with low-gradient “severe” stenosis (defined as aortic valve area 1.0 cm2 and mean gradient 40 mm Hg) in
the prospective Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.
Methods and Results—Outcome in patients with low-gradient “severe” aortic stenosis was compared with outcome in
patients with moderate stenosis (aortic valve area 1.0 to 1.5 cm2; mean gradient 25 to 40 mm Hg). The primary end point
of aortic valve events included death from cardiovascular causes, aortic valve replacement, and heart failure due to aortic
stenosis. Secondary end points were major cardiovascular events and cardiovascular death. In 1525 asymptomatic
patients (mean age, 6710 years; ejection fraction, 55%), baseline echocardiography revealed low-gradient severe
stenosis in 435 patients (29%) and moderate stenosis in 184 (12%). Left ventricular mass was lower in patients with
low-gradient severe stenosis than in those with moderate stenosis (18264 versus 21268 g; P0.01). During 46
months of follow-up, aortic valve events occurred in 48.5% versus 44.6%, respectively (P0.37; major cardiovascular
events, 50.9% versus 48.5%, P0.58; cardiovascular death, 7.8% versus 4.9%, P0.19). Low-gradient severe stenosis
patients with reduced stroke volume index (35 mL/m2; n223) had aortic valve events comparable to those in patients
with normal stroke volume index (46.2% versus 50.9%; P0.53).
Conclusions—Patients with low-gradient “severe” aortic stenosis and normal ejection fraction have an outcome similar to
that in patients with moderate stenosis. (Circulation. 2011;123:887-895.)
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In up to 30% of patients sent for echocardiographic evaluationof the severity of aortic stenosis, the clinician will be con-
fronted with a discrepancy in echocardiographic parameters
indicating severe stenosis based on aortic valve area but nonse-
vere stenosis based on mean pressure gradient despite a normal
ejection fraction.1 Recent retrospective studies have suggested
that such a low transvalvular gradient in the presence of a
calculated aortic valve area 1.0 cm2 and preserved ejection
fraction may be due to reduced stroke volume and that patients
with this constellation represent a subgroup with advanced stage
of severe aortic valve disease with impaired ventricular function
and poor prognosis requiring early valve surgery.2–5
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Evaluation and grading of aortic valve stenosis with
2-dimensional and Doppler echocardiography play key roles in
the management and assessment of prognosis of patients with
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aortic stenosis.6–11 Precise echocardiographic grading is of
particular importance in patients presenting with dyspnea suf-
fering from comorbidities such as chronic obstructive pulmonary
disease, hypertension, or obesity, in which the relation between
aortic stenosis and symptoms remains unclear. Current Ameri-
can and European guidelines both recommend an aortic valve
area partition value of 1.0 cm2 or, indexed by body surface
area, 0.6 cm2/m2 for severe aortic stenosis.10,12 Corresponding
values for peak transvalvular flow velocity are 4 m/s and for
mean pressure gradient 40 mm Hg in the presence of a
“normal” cardiac output.12 Moderate stenosis is characterized by
an aortic valve area between 1.0 and 1.5 cm2 and a mean
pressure gradient between 25 and 40 mm Hg.
In the present study, we investigated the prognostic impact
and progression rate of low-gradient “severe” aortic valve
stenosis in the prospective, randomized, multicenter Sim-
vastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.13,14
Patients and Methods
Patients
The SEAS study enrolled 1873 patients with asymptomatic aortic
stenosis, defined by echocardiography at local study centers as aortic
valve thickening and peak transaortic Doppler velocity 2.5 and
4.0 m/s. Patients were randomized from January 2001 to February
2004 to at least 4-year placebo-controlled combined treatment with
ezetimibe 10 mg/d and simvastatin 40 mg/d. Patients with coronary
heart disease, heart failure, diabetes mellitus, history of stroke or
peripheral vascular disease, clinically significant mitral valve dis-
ease, severe or predominant aortic regurgitation, rheumatic valvular
disease, aortic valve prosthesis, or renal insufficiency and patients
already on lipid-lowering therapy or having an indication for lipid
lowering according to guidelines were excluded. The SEAS study
was approved by regional ethics committees in all participating
countries, and all patients gave written informed consent. In the
individual patient, the decision to proceed to valve replacement was
made by the treating physician according to the recommendations in
current guidelines. Design of and results from the SEAS study have
been published recently,13,14 showing no difference in major cardio-
vascular events between the treatment and placebo groups but a
significant reduction in ischemic events in patients treated with
ezetimibe/simvastatin.
Echocardiography
Baseline echocardiograms were obtained with the use of echocar-
diographs with second harmonic imaging and following a standard-
ized protocol in all participating hospitals.13 All echocardiograms
were sent for central interpretation at the SEAS echocardiography
core laboratory at Haukeland University Hospital, Bergen, Norway.
Subaortic and transaortic blood flow velocities and gradients were
derived from velocity time integrals, measured by pulsed-wave
Doppler in the left ventricular outflow tract (LVOT) near the aortic
valve and by continuous-wave Doppler from different (including
right parasternal and suprasternal) windows by imaging and nonim-
aging transducers, respectively. The highest transaortic velocity was
used for tracing of the time-velocity integral. Aortic valve annulus
was measured at end-diastole in the 2-dimensional parasternal
long-axis view by an inner-edge-to-inner-edge method.15 The effec-
tive aortic valve area was calculated with the continuity equation.11
Stroke volume was calculated as the product of velocity time integral
of subvalvular flow velocity and aortic annulus area. A detailed
description of the echocardiographic protocol has been published
previously.16
Definition of Severity of Aortic Valve Stenosis
Adhering to the partition values shown in current American guide-
lines,12 we defined 2 types of aortic stenosis: low-gradient “severe”
aortic stenosis characterized by a discrepancy in echocardiographic
parameters indicating severe stenosis based on aortic valve area but
nonsevere stenosis based on mean pressure gradient (aortic valve
area 1.0 cm2; mean pressure gradient 40 mm Hg)1 and moderate
aortic valve stenosis fulfilling both criteria for moderate stenosis
(aortic valve area 1.0 to 1.5 cm2; mean pressure gradient 25 to
40 mm Hg).
End Points
The primary end point of the present study was aortic valve events
(defined as aortic valve replacement, congestive heart failure due to
aortic stenosis, or death from cardiovascular causes). Secondary end
points included major cardiovascular events (a composite of death
from cardiovascular causes, aortic valve replacement, congestive
heart failure as a result of progression of aortic valve stenosis,
nonfatal myocardial infarction, hospitalization for unstable angina,
coronary artery bypass grafting, percutaneous coronary intervention,
or nonhemorrhagic stroke) and ischemic events (defined as death
from cardiovascular causes, nonfatal myocardial infarction, hospi-
talization for unstable angina, coronary artery bypass grafting,
percutaneous coronary intervention, or nonhemorrhagic stroke).
Finally, rates of cardiovascular death were analyzed separately. All
end points were adjudicated with a predefined end point protocol by
an end point committee blinded for the original study conduct and
results.
Outcome
Outcome over the entire follow-up as indicated by the primary and
secondary end points was compared between patients with low-gradient
“severe” aortic stenosis and patients with moderate stenosis on baseline
echocardiography. We also analyzed outcome at the end of the first year
of follow-up separately because the assignment of a given stenosis to a
particular category (low-gradient “severe” aortic stenosis versus mod-
erate stenosis versus severe stenosis) may change over time because of
the progressive nature of the disease, and yearly echocardiographic
assessment is recommended in current guidelines.12 Because low stroke
volume has been proposed to represent an important reason for a low
transvalvular gradient in the presence of a normal ejection fraction, and
low stroke volume index has indicated a worse prognosis in a recent
study,3 we also evaluated outcome in patients with low-gradient “se-
vere” aortic stenosis according to stroke volume index. A reduced stroke
volume index was defined as 35 mL/m2 and a normal stroke volume
index as35 mL/m2. Finally, outcome was compared between patients
with and without valve replacement because a negative impact of
low-gradient “severe” aortic stenosis could have been masked by the
inclusion of valve replacements in the primary end point.
Statistical Analysis
Data are presented as meanSD or as counts or proportions (%).
Categorical data were compared with the use of Fisher exact test when
expected cell values were 5. The Yates correction factor was applied
to comparisons of groups with small numbers. Continuous data were
compared with Student t test, irrespective of multiple testing procedures.
To account for different follow-up lengths, annualized rates were
calculated by dividing the total event rates by length of follow-up. The
Kaplan-Meier method was used to assess event-free survival with
differences checked by means of the log-rank test. Cox proportional
hazards models including the variables age, gender, smoking status,
heart rate, and hypertension were calculated for estimating hazard ratio
(HR) for event-free survival. Although aortic valve events, major
cardiovascular events, and cardiovascular death were found not to be
different in the treatment versus the placebo group in the main SEAS
study, the variable randomized treatment was entered into the model as
a forced variable. Statistical significance was accepted for a 2-sided
P0.05.
Results
The present study population comprises 1525 (81.4%) of the
1873 patients recruited in the SEAS trial14 with an ejection
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fraction 55% in whom a detailed echocardiographic assess-
ment by the core laboratory at baseline was available.
Low-gradient “severe” aortic stenosis was present in 435
(29%) of the study population and moderate stenosis in 184
(12%). Severe stenosis (mean pressure gradient 40 mm Hg
and aortic valve area 1.0 cm2) was observed in a limited
number of patients (n35; 2%) because of reassessment of
locally obtained echocardiographic data at the core laboratory
after randomization. Twenty-one patients (1%) had a mean
pressure gradient 40 mm Hg with an aortic valve area 1.0
cm2, and the remainder (n850; 56%) had mild stenosis
(mean pressure gradient 25 mm Hg and/or aortic valve area
1.5 cm2).
Low-Gradient “Severe” Aortic Stenosis Versus
Moderate Stenosis
Patients with low-gradient “severe” aortic stenosis were older,
smaller, and more often female and had higher systolic blood
pressure than patients with moderate stenosis. Body mass index
was comparable (Table 1). Echocardiographic parameters for
patients with low-gradient “severe” aortic stenosis and moderate
stenosis are shown in Table 2. Patients with low-gradient
“severe” aortic stenosis had a lower mean pressure gradient and
a smaller aortic valve area than patients with moderate stenosis.
Left ventricular end-diastolic diameter, mass, outflow tract
diameter, and stroke volume index were significantly lower in
patients with low-gradient “severe” aortic stenosis than in
patients with moderate stenosis, whereas ejection fraction was
comparable between groups.
At the end of the first year of follow-up, there were few
aortic valve events (3.2% versus 3.8%; P0.71) both for
patients with low-gradient “severe” aortic stenosis and for
patients with moderate aortic stenosis. Similarly, there were
no significant differences between groups with respect to
major cardiovascular events (4.8% versus 4.3%; P0.80) and
cardiovascular death (1.1% versus 0.5%; P0.49). Outcome
over the entire follow-up (mean of 45.814.1 months) is
summarized in Table 3. There was no significant difference
between patients with low-gradient “severe” aortic stenosis
and moderate stenosis with respect to all predefined end
points. Kaplan-Meier curves for event-free survival from
aortic valve events, major cardiovascular events, and cardio-
vascular death are depicted in Figure 1A through 1C.
Similarly, annualized rates of aortic valve events
(13.81.0% versus 12.71.4%; P0.43), major cardiovas-
cular events (14.81.0% versus 14.11.5%; P0.59), and
cardiovascular death (1.80.3% versus 1.10.4%; P0.18)
showed no significant difference between patients with low-
gradient severe aortic stenosis and those with moderate
stenosis.
Table 1. Baseline Characteristics
Aortic Valve Stenosis
Low-Gradient “Severe”
(AVA1.0 cm2;
MPG40 mm Hg)
(n435)
Moderate
(AVA 1.5–1.0 cm2;
MPG 25–40 mm Hg)
(n184) P
Age, y 69.89.2 66.89.2 0.01
Female gender, n (%) 240 (55.2) 50 (27.2) 0.01
Height, cm 167.28.8 173.28.7 0.01
Weight, kg 74.413.6 80.213.1 0.01
Body surface area, m2 1.830.2 1.940.2 0.01
Body mass index, kg/m2 26.64.3 26.73.9 0.69
Whites, n (%) 432 (99.2) 184 (100) 0.53
Heart rate, bpm 68.210.2 68.011.0 0.81
Blood pressure, mm Hg
Systolic 145.821.1 142.220.4 0.05
Diastolic 82.110.7 81.59.3 0.52
Hypertension, n (%) 213 (49.0) 93 (50.5) 0.72
Smoking, n (%) 0.01
Current 73 (16.8) 40 (21.7)
Former 144 (33.1) 77 (41.8)
Never 218 (50.1) 67 (36.4)
Glucose, mg/dL 95.816,4 94.211.7 0.29
Creatinine, mg/dL 1.030.17 1.090.19 0.01
Cholesterol, mg/dL
Total 225.837.9 219.637.9 0.06
Low-density lipoprotein 140.833.3 136.137.1 0.15
Clinical characteristics of 619 patients included in the SEAS trial14 according to baseline echocardiographic
assessment of aortic valve stenosis as either low-gradient “severe” stenosis (aortic valve area AVA 1.0 cm2 and
mean pressure gradient MPG40 mm Hg) or moderate stenosis (aortic valve area 1.5–1.0 cm2 and mean pressure
gradient 25–40 mm Hg).
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In multivariate Cox regression analysis controlling for the
effects of age, gender, smoking, heart rate, hypertension, and,
as a forced entry, treatment allocation (ezetimibe/simvastatin
versus placebo), low-gradient “severe” aortic stenosis was not
an independent predictor for aortic valve events (HR, 1.01
[confidence interval, 0.94 to 1.23]; P0.29; Table 4), major
cardiovascular events (HR, 1.06 [confidence interval, 0.92 to
1.20]; P0.41), or cardiovascular death (HR, 1.15 [confi-
dence interval, 0.79 to 1.67]; P0.48).
Stroke Volume Index
In patients with low-gradient severe stenosis, a reduced
stroke volume index of 35 mL/m2 was diagnosed in 223
individuals (51%) (mean, 294 mL/m2). Mean pressure
gradient (247 versus 297 mm Hg; P0.01) was lower
and aortic valve area (0.770.1 versus 0.880.1 cm2;
P0.01) was smaller than in patients with a normal stroke
volume index (35 mL/m2; mean, 415 mL/m2). Ejection
fraction (66.75.8% versus 67.25.6%; P0.45) was
comparable between groups. Patients with a reduced stroke
volume index suffered an aortic valve event during
follow-up in 46.2%, which was not significantly different
from patients with a normal stroke volume index (50.9%;
P0.53; Figure 2; major cardiovascular events, 49.8%
versus 51.9%; P0.94). Similarly, cardiovascular death
was comparable in both groups (8.1% versus 7.5%;
P0.77).
Outcome With and Without Valve Replacement
In a separate analysis restricted to patients who did not undergo
valve replacement (252 patients with low-gradient “severe”
aortic stenosis and 108 with moderate stenosis), no significant
difference was found in major cardiovascular events (15.1%
versus 12.0%; P0.45) or cardiovascular death (9.1% versus
5.6%; P0.25). Furthermore, in the group of patients with
low-gradient severe stenosis, cardiovascular death rates were
Table 2. Baseline Echocardiographic Parameters
Aortic Valve Stenosis
Low-Gradient “Severe”
(AVA1.0 cm2;
MPG40 mm Hg)
(n435)
Moderate
(AVA 1.5–1.0 cm2;
MPG 25–40 mm Hg)
(n184) P
Aortic valve
Peak aortic jet velocity, m/s 3.30.5 3.60.3 0.01
Transaortic peak pressure gradient, mm Hg 44.811.9 53.07.4 0.01
Transaortic mean pressure gradient, mm Hg 26.27.3 31.24.1 0.01
Aortic valve area, cm2 0.820.13 1.190.13 0.01
Aortic valve area index, cm2/m2 0.460.08 0.630.09 0.01
Velocity time integral aortic valve, cm 78.013.0 82.010.0 0.01
Dimensionless velocity index 0.260.06 0.300.06 0.01
Stroke volume
LV outflow tract diameter, mm 20.20.2 22.80.2 0.01
Velocity time integral LV outflow tract, cm 20.14.1 24.24.9 0.01
Stoke volume, mL 63.813.1 97.513.9 0.01
Stoke volume index, mL/m2 35.17.3 50.78.5 0.01
Cardiac output, L/min 4.31.0 6.61.2 0.01
Cardiac index, L/min 2.40.56 3.40.71 0.01
LV
LV ejection fraction, % 66.95.7 66.75.8 0.68
LV end-diastolic diameter, mm 49.06.1 50.75.6 0.01
LV end-diastolic diameter index, mm/m2 26.93.4 26.33.2 0.04
LV end-diastolic volume, mL 115.332.7 124.431.1 0.01
LV end-diastolic volume index, mL/m2 63.016.5 64.315.6 0.36
LV end-systolic diameter, mm 31.05.1 31.65.0 0.18
LV end-systolic diameter index, mm/m2 17.02.7 16.42.7 0.01
Fractional shortening, % 36.85.6 37.86.0 0.05
LV end-diastolic septum thickness, mm 11.42.8 12.32.9 0.01
LV end-diastolic posterior wall thickness, mm 8.81.9 9.41.9 0.01
LV mass, g 182.363.6 211.667.5 0.01
LV mass index, g/m2 98.930.6 108.933.3 0.01
Relative wall thickness, % 36.59.5 37.38.9 0.30
Baseline echocardiographic measures in 619 patients included in the SEAS trial14 according to assessment of aortic
valve stenosis as either low-gradient “severe” or moderate stenosis. AVA indicates aortic valve area; MPG, mean
pressure gradient; and LV, left ventricular.
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comparable between those patients who underwent valve re-
placement (11/183; 6.0%) and those who were followed conser-
vatively (23/252; 9.1%; P0.23).
Low-Gradient “Severe” Aortic Stenosis Versus
Severe Aortic Stenosis
Thirty-five patients randomized for the SEAS study fulfilled
both criteria for severe stenosis (mean pressure gradient
40 mm Hg and aortic valve area 1.0 cm2). Patients with
severe stenosis experienced an aortic valve event in 74.3%
(low-gradient “severe” aortic stenosis, 48.5%; P0.01; Figure
1) and a major cardiovascular event also in 74.3% (low-gradient
“severe” aortic stenosis, 50.9%; P0.01) because all major
cardiovascular events were due to aortic valve events. Rates of
cardiovascular death were similar in both groups (7.8% versus
5.7%; P0.65).
Figure 1. Kaplan-Meier plots for freedom from aortic valve
events, major cardiovascular events, and cardiovascular death
(A, B, and C, respectively) in patients with low-gradient “severe”
aortic stenosis (LGSAS) (aortic valve area 1.0 cm2; mean pres-
sure gradient 40 mm Hg) and moderate aortic stenosis (AS)
(aortic valve area 1.5 to 1.0 cm2; mean pressure gradient 25 to
40 mm Hg). There was no statistically significant difference by
means of the log-rank test between low-gradient severe and
moderate stenosis (aortic valve events, P0.48; major cardio-
vascular events, P0.64; cardiovascular death, P0.19). For
comparison, event rates of a small group of patients (n35) with
severe stenosis (aortic valve area 1.0.cm2, mean pressure gra-
dient 40 mm Hg) are shown in gray.
Table 3. Primary and Secondary Outcomes
Aortic Valve Stenosis
Low-Gradient “Severe”
(AVA1.0 cm2;
MPG 40 mmHg)
(n435)
Moderate
(AVA 1.5–1.0 cm2;
MPG 25–40 mmHg)
(n184)
Aortic valve events, n (%) 211 (48.5) 82 (44.6)
Aortic valve replacement 183 (42,1) 76 (41.3)
Congestive heart failure
due to aortic stenosis
17 (3.9) 4 (2.2)
Death from cardiovascular
cause
34 (7.8) 9 (4.9)
Major cardiovascular
events, n (%)
221 (50.9) 89 (48.4)
Death from cardiovascular
cause, n (%)
34 (7.8) 9 (4.9)
Related to cardiac
surgery
6 (1.4) 2 (1.1)
Heart failure 2 (0.5) 2 (1.1)
Myocardial infarction 5 (1.1) 1 (0.5)
Stroke 6 (1.4) 0 (0)
Sudden death 12 (2.8) 2 (1.1)
Other cardiovascular
death
3 (0.7) 2 (1.1)
Overall death 56 (12.9) 19 (10.3)
Ischemic events, n (%) 102 (23.4) 40 (21.7)
Nonfatal myocardial
infarction
12 (2.8) 2 (1.1)
Coronary artery bypass
grafting
53 (12.2) 22 (12.0)
Percutaneous coronary
intervention
7 (1.6) 1 (0.5)
Hospitalization for
unstable angina
2 (0.5) 0 (0)
Nonhemorrhagic stroke 21 (4.8) 8 (4.3)
Death from cardiovascular
cause
34 (7.8) 9 (4.9)
Aortic valve events, major cardiovascular events, death from cardiovascular
causes, ischemic events, and their components according to the assessment of
aortic valve stenosis at baseline as either low-gradient “severe” or moderate
stenosis. AVA indicates aortic valve area; MPG, mean pressure gradient.
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Progression and Outcome According to the Last
Available Echocardiogram
Data from the last echocardiogram before an end point (or
before the termination of the study in patients who did not
reach an end point) showed that of the 1326 patients with
complete echocardiographic data, 319 (24%) had reached the
stage of severe stenosis, 275 (21%) had low-gradient “severe”
aortic stenosis, and 216 (16%) had moderate stenosis. Pro-
gression to severe stenosis was observed in 62 of 163 patients
(38%) with moderate stenosis and in 154 of 374 (41%) with
low-gradient “severe” aortic stenosis at baseline (P0.50).
Aortic valve events and major cardiovascular events were
comparable between patients with low-gradient “severe”
aortic stenosis and moderate stenosis (aortic valve events,
26.2% versus 24.5%; major cardiovascular events, 29.5%
versus 26.4%; both PNS). In contrast, patients with severe
stenosis had experienced more aortic valve events (53.9%)
and major cardiovascular events (56.4%) than patients with
low-gradient severe aortic stenosis or patients with moderate
stenosis (both P0.01). No difference between groups was
noted with respect to cardiovascular deaths (low-gradient
“severe” aortic stenosis, 2.5%; moderate stenosis, 1.9%; and
severe stenosis, 4.7%; PNS).
Discussion
The present study, based on the largest prospective trial in aortic
stenosis to date, demonstrates that low-gradient “severe” aortic
stenosis (aortic valve area 1.0 cm2; mean pressure gradient
40 mm Hg) is a frequent echocardiographic constellation in
asymptomatic patients with preserved left ventricular function
(ejection fraction 55%). The associated echocardiographic
characteristics denote no more than moderate aortic valve
disease. Outcome and progression rate in patients with
low-gradient “severe” aortic stenosis are similar to those in
patients with moderate stenosis with a markedly better out-
come than reported previously. Consistent results were observed
in both medically and surgically treated patients. Low-gradient
“severe” aortic valve stenosis was associated with a decreased
stroke volume index in 51% of cases, with no difference in
outcome between patients with reduced and normal flow. There-
fore, low-gradient “severe” aortic stenosis, in general, does not
indicate severe aortic valve disease, and patients can be followed
safely with serial clinical and echocardiographic evaluations.
These prospectively collected results are in contrast to
recent retrospective studies,2–5 which have suggested that
patients with low-gradient “severe” aortic stenosis may rep-
resent a subgroup with an advanced stage of severe aortic
stenosis with reduced stroke volume due to impaired ventric-
ular function despite preserved ejection fraction and resultant
poor prognosis, particularly when early valve replacement is
withheld.
A number of characteristics of the previous retrospective
studies may explain the divergent results to the present analysis.
First, previous studies included patients with an ejection fraction
as low as 50%, which in the presence of concentric left
ventricular remodeling cannot be considered normal. An adverse
outcome in patients with reduced stroke volume may be ex-
plained by the overrepresentation of patients with reduced
Table 4. Multivariate Analysis
Variable
Aortic Valve Events Major Cardiovascular Events Cardiovascular Death
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Low-gradient “severe” aortic stenosis 1.01 (0.94–1.23) 0.29 1.06 (0.92–1.20) 0.41 1.15 (0.79–1.67) 0.48
Gender, female 0.76 (0.59–0.98) 0.03 0.73 (0.57–0.93) 0.01 0.57 (0.30–1.10) 0.09
Heart rate 1.01 (1.00–1.03) 0.02 1.01 (1.00–1.02) 0.02 1.04 (1.01–1.07) 0.01
Age 1.01 (0.99–1.02) 0.25 1.01 (1.00–1.02) 0.20 1.16 (1.10–1.22) 0.01
Smoking, former 1.14 (0.81–1.59) 0.45 1.17 (0.84–1.63) 0.36 0.45 (0.19–1.04) 0.06
Smoking, never 0.96 (0.69–1.35) 0.83 1.06 (0.76–1.48) 0.72 0.41 (0.17–0.96) 0.04
Blood pressure, systolic 1.00 (0.99–1.01) 0.82 1.00 (0.99–1.01) 0.99 1.01 (0.99–1.02) 0.41
Treatment allocation 0.94 (0.75–1.19) 0.61 0.92 (0.73–1.15) 0.46 1.01 (0.55–1.85) 0.99
CI indicates confidence interval. Multivariate analysis including patients with low-gradient “severe” and moderate stenosis (n619), indicating that the
echocardiographic constellation of low-gradient “severe” aortic stenosis (aortic valve area 1.0 cm2; and mean pressure gradient 40 mm Hg) was not an
independent predictor of aortic valve events, major cardiovascular events, or cardiovascular death. Male gender and an increased heart rate were predictive of aortic
valve and major cardiovascular events. An increased age and heart rate and smoking status were predictive of cardiovascular death. Treatment allocation specifies
treatment with ezetimibe/simvastatin vs placebo in the original SEAS trial.14
Figure 2. Kaplan-Meier plots for freedom from aortic valve
events in patients with low-gradient “severe” aortic valve steno-
sis (n435) stratified according to reduced stroke volume index
(SVI) (35 mL/m2; n223) and normal stroke volume index (35
mL/m2; n212). There was no statistically significant difference
in event-free survival after a mean follow-up of 46 months
between the 2 groups (53.8% versus 49.1%, respectively;
P0.53).
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ejection fraction in the low-flow group. Second, patients in
previous studies were selected consecutively according to a
single echocardiographic study irrespective of comorbidities.
Therefore, the group of “medically treated” patients may include
a certain number of individuals with poor functional status and
prognosis. Some of these patients may be unable to undergo
surgery because of reasons other than aortic stenosis. Third,
aortic valve replacement and death were the only events rec-
orded during follow-up. No information is available about
clinical course and cause of death. Fourth, there was a high
prevalence of coronary artery disease, with outcome in these
patients markedly influenced by ischemic events. An improved
survival in surgically treated patients may therefore be due in
part to concomitant bypass surgery. In contrast, we included
only patients with an ejection fraction55%. All patients in the
SEAS study were carefully monitored prospectively for an
extended period of time (mean, 46 months) with scheduled
clinical visits, regular echocardiographic assessment, timely
surgery according to guidelines, and systematic assessment of
cause of death. Patients with coronary heart disease and other
overt comorbidities at baseline, including diabetes mellitus, renal
insufficiency, history of stroke or peripheral vascular disease, or
the indication for lipid-lowering therapy, were excluded. There-
fore, the present analysis allows for the assessment of outcome
predominantly determined by aortic stenosis.
An additional difference is the fact that retrospective
studies did not report on symptom status.3,4 However, the
presence of symptoms has an important impact on outcome
and clinical management in patients with aortic stenosis.
Because patients in the previous studies had been included
consecutively, it is likely that both symptomatic and asymp-
tomatic patients had been recruited with unknown distribu-
tion to different subgroups. Therefore, conclusions about
clinical management and the need and timing of valve
replacement should be interpreted with caution. In contrast,
the present analysis was restricted to asymptomatic patients at
baseline, showing that low-gradient “severe” aortic stenosis is
a frequent finding in these patients and is associated with a
markedly better outcome than previously reported when
patients are followed carefully. Fifty percent of patients
remain event free and do not require surgery over 46 months
despite the progressive nature of aortic valve disease, indi-
cating that low-gradient severe stenosis per se does not
represent an advanced stage of aortic valve disease.
Mechanisms of Low-Gradient “Severe”
Aortic Stenosis
Several unrelated mechanisms may account for a low pressure
gradient in combination with a severely stenotic aortic valve area
in the presence of a preserved ejection fraction. First, low
pressure gradient in the presence of a severe aortic stenosis may
be the result of reduced stroke volume despite preserved ejection
fraction due to decreased ventricular size and/or impaired myo-
cardial function.3,16 However, a low stroke volume index was
found in only one half of patients with low-gradient “severe”
aortic stenosis in the present study, confirming previous findings
that low stroke volume may only partly explain this constella-
tion.1 Second, low-gradient “severe” aortic stenosis in the
presence of a normal stroke volume may be due to inconsisten-
cies in current guidelines regarding the partition value for severe
stenosis. We and others have recently shown that low-gradient
“severe” aortic stenosis can be observed in the presence of
normal stroke volume even when catheter-based calculations are
used,17–19 indicating that a valve area of 1.0 cm2 usually does not
correlate with a mean pressure gradient of 40 mm Hg. Third,
patients with small body size and left ventricular dimensions
may exhibit a lower transvalvular pressure gradient because of a
lower albeit normal stroke volume. Indeed, our data show that
patients with low-gradient “severe” aortic stenosis had smaller
body size and left ventricular dimensions compared with patients
with moderate stenosis. Fourth, difficulties in proper calculation
of aortic valve area may be a reason for the observation of
low-gradient “severe” aortic stenosis. Echocardiography tends to
underestimate the LVOT diameter partially owing to its elliptic
rather than circular anatomy.20–22 Because the square of the
radius is used in the continuity equation, small errors in the
measurement of the LVOT diameter will result in a substantial
error in aortic valve area. To minimize the error in calculating
LVOT area, we measured aortic annulus diameter instead of
LVOT in the present study because the former has been shown
to be similar in size but less eccentric.23 Finally, an increase in
systemic blood pressure may decrease transvalvular pressure
gradient.24 As a result, more patients will be diagnosed with
low-gradient “severe” aortic stenosis, which, in turn, may
explain the increased number of patients with elevated blood
pressure in the low-gradient “severe” aortic stenosis group in the
present analysis. However, the effects of blood pressure on the
echocardiographic assessment of mean pressure gradient and
aortic valve area remain controversial.25
Clinical Implications
The echocardiographic constellation of low-gradient “severe”
aortic valve stenosis in patients with normal ejection fraction
is a clinically challenging finding observed in 30% of
consecutive, unselected patients evaluated for aortic steno-
sis,1,3,4 The present study and a previous study26 demonstrate
that it is also present in 29% of asymptomatic patients, of
whom many remain event free over a considerable period of
time independently of calculated stroke volume index. There-
fore, management of asymptomatic patients similar to those
with moderate stenosis is reasonable, including clinical and
echocardiographic follow-up every 6 months, as in the SEAS
trial, or yearly, as recommended by current guidelines.
Functional capacity of the asymptomatic patient may be
assessed by exercise testing.27,28
In patients with low-gradient severe stenosis presenting
with dyspnea suffering from comorbidities such as chronic
obstructive pulmonary disease, hypertension, or obesity, the
relation between aortic stenosis and symptoms needs clarifi-
cation and further evaluation, particularly when surgery is
considered, because a higher perioperative risk may have to
be anticipated, and aortic stenosis may not be the reason for
their symptoms. An accurate estimation of the severity of
aortic stenosis, assessment of comorbidities, particularly the
presence of coronary artery disease, and the risk carried by
the individual patient is warranted. Hence, if “the numbers
don’t add up,”29,30 all echocardiographic measurements
should be rechecked carefully. This is especially true for the
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measurement of the LVOT diameter, representing the Achil-
les’ heel of the calculation of aortic valve area by the
continuity equation. Other diagnostic tools should be consid-
ered to assess morphology and hemodynamics of the stenotic
valve. This may include transesophageal echocardiography,31
magnetic resonance imaging,32 and, rarely, cardiac catheter-
ization,33 as outlined in the American Heart Association/
American College of Cardiology and European Society of
Cardiology guidelines.10–12 Several additional echocardio-
graphic parameters have been proposed for a better definition
of the severity of aortic stenosis and imminent risk (energy
loss index,34,35 stroke work loss,36,37 resistance,38 and valvu-
loarterial impedance39,40), but their utility and prognostic
impact still must be proven in larger-scale, prospective
studies. Indication for valve replacement in patients with
low-gradient “severe” aortic stenosis may currently be re-
stricted to those in whom symptoms can clearly be attributed
to aortic valve disease. The remainder requires close clinical
monitoring for development of symptoms and disease
progression.
Limitations
Although the data were collected prospectively, the current
analysis was performed retrospectively with all its inherent
limitations. In the present study, only patients with an
ejection fraction 55% were included, which in the presence
of left ventricular hypertrophy may not be entirely normal.
Therefore, some patients may have had undetected left
ventricular compromise. Patients in the SEAS trial were
scheduled for surgical valve replacement according to current
guidelines. However, echocardiographic calculation of mean
pressure gradient and aortic valve area may have influenced
the decision. Yet, patients with low-gradient “severe” aortic
stenosis had an outcome comparable to that of patients with
moderate stenosis in both surgically and conservatively man-
aged patients. The comparison to patients with severe aortic
stenosis is limited because the SEAS study was designed to
include patients with mild to moderate aortic stenosis. The 35
patients identified as having severe aortic stenosis after
review of the echocardiographic data at the core laboratory
therefore represent a subgroup of patients at the lower end of
the spectrum of severe aortic stenosis. Although these pa-
tients already have markedly higher event rates than patients
with moderate and low-gradient “severe” aortic stenosis,
patients with “very severe”9 aortic stenosis can be expected to
have an even worse outcome.
Conclusion
Outcome and progression rate in patients with low-gradient
“severe” aortic valve stenosis are similar to those in patients
with moderate stenosis. The echocardiographic finding of an
aortic valve area 1.0 cm2 and a mean pressure gradient
40 mm Hg is frequent in asymptomatic patients with
preserved ejection fraction and in general does not indicate
advanced aortic valve disease. Indication for valve replace-
ment may safely be restricted to those in whom symptoms
can clearly be attributed to aortic stenosis.
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CLINICAL PERSPECTIVE
This is the first prospective study to determine the outcome of patients with low-gradient “severe” aortic valve stenosis,
defined as a severe stenosis based on aortic valve area (1.0 cm2) and a nonsevere stenosis based on mean pressure
gradient (40 mm Hg). In an analysis of 1525 patients with preserved ejection fraction from the Ezitimibe/Simvastatin in
Aortic Stenosis (SEAS) trial, we confirm that this clinically challenging finding is also present in 29% of asymptomatic
patients, similar to the percentage observed in unselected patients evaluated for aortic stenosis. The associated
echocardiographic characteristics (eg, left ventricular mass) denote no more than moderate aortic valve disease.
Comparison to patients with moderate stenosis (aortic valve area 1.0–1.5 cm2/mean pressure gradient 25–40 mm Hg)
shows a similar progression rate to truly severe stenosis (aortic valve area 1.0 cm2/mean pressure gradient 40 mm Hg)
and overall outcome during 46 months of follow-up (aortic valve events 48.5% vs 44.6%; P0.37). These results indicate
a markedly better prognosis in patients with low-gradient “severe” aortic stenosis than suggested in recent retrospective
studies. According to our results, patients with low-gradient “severe” aortic stenosis can be managed with serial clinical
and echocardiographic evaluations. Surgery is recommended only when symptoms can clearly be attributed to aortic
stenosis or other indications according to prevailing guidelines.
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